This Statement is made pursuant to section 54 of the Act and constitutes the Modern Slavery and Human Trafficking Statement for the Financial Year ended 31st December 2024 for Mundipharma International Ltd.
Overview
Mundipharma International Limited is a member of a global network of independent associated companies within the Mundipharma global business (Mundipharma). The Company provides business services to related party clients within the pharmaceutical sector.
Following the introduction of the Modern Slavery Act 2015 (subsequently amended by the Modern Slavery (Amendment) Bill 2021) (the “Act”), we analyze the risks within our own business and our supply network annually. Having analyzed the risks within our business and supply network, we are not currently aware of any areas likely to lead to a breach of human rights and the Act. We do not believe our risk in our operations and supply chain for the period 1 January to 31 December 2024 has changed since our previous Statement for the financial year ended 31 December 2023. We remain committed and it is our policy to never knowingly deal with any organisation connected to slavery, human trafficking or child exploitation of any kind.
Our business is committed to operating in an ethical and transparent manner, in line with this commitment, Mundipharma International Limited has incorporated into our Global Code of Conduct the requirements of the Act. We take the upholding of these high standards seriously and do not tolerate slavery or human trafficking within our organisation or from those whom we acquire products or services. We have implemented a Code of Conduct for Third Parties that sets out our expectations of our third-party partners across multiple areas including health and safety, human rights (modern slavery, human trafficking or child labour) and sustainability. Human rights concerns are specifically mentioned in our Third-Party Code of Conduct as practices that we require our suppliers to prohibit. The Third-Party Code of Conduct and modern slavery clauses have been incorporated into our agreements.
During 2024 Mundipharma set up the ESG Steering Group, the primary purpose being to oversee, identify principal risks and implement appropriate measures to effectively monitor, manage and drive patient centricity and sustainable operations within the Mundipharma business.
Policies, contract clauses, training, communication and the raising of concerns
The Board of Directors, senior management and senior leaders including the supply chain and procurement functions are aware of the modern slavery obligations contained within the Act. Mundipharma International Limited recognizes that a key component of managing and mitigating modern slavery risks in our operations and supply chain is the ongoing raising of awareness of modern slavery and the ensuring of ethical and fair practices in our business operations. As a consequence of the Mundipharma policies currently in place within the business, Mundipharma International Limited has an environment which encourages open and frank two-way communication, and employees are encouraged and expected to raise concerns about any known or suspected violation of the Global Code of Conduct or other illegal or unethical business conduct. The Global Code of Conduct and Global Anti-Bribery and Anti-Corruption Policies provide a foundation for acting with integrity for all employees. There is a standard operating procedure in place for safeguarding and protecting whistleblowers from retaliation, therefore the current business culture encourages reporting of misconduct including the reporting of ethical concerns. Any concerns can be raised in confidence without fear of retaliation by approaching Management, HR, Legal or Compliance. Alternatively, individuals may report their concerns, and if desired remain anonymous, through our on-line reporting hotline (integrityline.mundipharma.com) which is available 24 hours a day. We do not tolerate any form of bullying, discrimination or harassment as outlined in our Anti-Bullying Policy and our Equal Employment Opportunity, Anti-Discrimination and Harassment Policy. Any concerns raised will be reviewed and, if required, investigated to determine appropriate action(s) where required. We aim on an ongoing basis to continue to equip those employees involved in procurement activities, with both the knowledge and understanding of the importance of the Act and the roles that employees play in helping to eradicate modern slavery, trafficking, and child exploitation..
Employment Practices
Our employment practices are compliant with applicable employment and health and safety legislation, and as a result, we are confident that there is no slavery or human trafficking taking place within our organisation. Furthermore, we ensure that the employment agencies that we deal with are fully compliant with the Act and applicable legislation (having enshrined within their policies and processes, mechanisms for the identification of the risks associated with modern slavery, including such practices leading to the introduction of various laws in the employment field).
Due Diligence
We aim to continually improve transparency within our business and the supply chain and not to work with any supplier that we suspect is connected in any way with slavery or human trafficking. As part of our Compliance Programme, we take steps to assure ourselves that we only partner with third parties that are fit and proper. We operate a risk based due diligence procedure covering third party relationships or partners. The due diligence process involves assessing the third party where appropriate, through completion of a questionnaire, business justification review and background checks (including screening against watchlists and adverse media) of third-party organisations.
Monitoring and Enforcement
We will continue to raise awareness and to monitor third-party supplier and partner relationships and continue to mitigate the risk of modern slavery. We acknowledge that there is more to be done in relation to preventing modern slavery and are committed to continually enhancing the Modern Slavery framework in future years. Any suspected breach of our Compliance Programme or of our Third-Party Code of Conduct, including the Act, will be investigated and such investigations could lead to the termination of supplier contracts and other actions being taken, as may be appropriate.
Conclusion
Due diligence activities during the financial year ending 31 December 2024 did not identify any instances of slavery, human trafficking or child exploitation within the business or the businesses of its suppliers, customers or service providers, therefore Mundipharma International Limited is currently not aware of any slavery or human trafficking taking place. Mundipharma International Limited will continue to apply appropriate risk based due diligence processes and approaches, as it continually enhances the Modern Slavery framework. It will continue to raise awareness and to monitor supplier relationships to mitigate the risk of modern slavery.
This Statement was approved by the Board of Mundipharma International Limited on 30 June 2025.
Bryan Lea, Director
Modern Slavery and Human Trafficking Statement for the year ending 31 December 2020
Modern Slavery and Human Trafficking Statement for the year ending 31 December 2019
Modern Slavery and Human Trafficking Statement for the year ending 31 December 2018
Modern Slavery and Human Trafficking Statement for the year ending 31 December 2017
Modern Slavery and Human Trafficking Statement for the year ending 31 December 2016